HALO Historical PE Ratio image   This HALO PE ratio history page last updated 11/10/2022
HALO Historical PE Ratio Chart
PeriodPriceAdj. EPSAnnualizedPE
Q3 2022
11/8/2022
45.830.742.9615.5
Q2 2022
8/9/2022
43.330.532.1220.4
Q1 2022
5/10/2022
38.200.471.8820.3
Q4 2021
2/22/2022
32.790.421.6819.5
Q3 2021
11/2/2021
39.490.552.2017.9
Q2 2021
8/9/2021
40.440.662.6415.3
Q1 2021
5/10/2021
46.100.371.4831.1
Q4 2020
2/23/2021
47.210.502.0023.6
Q3 2020
11/2/2020
28.400.251.0028.4
Q2 2020
8/10/2020
28.640.190.7637.7
Q1 2020
5/11/2020
24.82-0.04-0.16NA
Q4 2019
2/24/2020
21.43-0.24-0.96NA
Q3 2019
11/12/2019
16.77-0.17-0.68NA
Q2 2019
8/6/2019
17.15-0.10-0.40NA
Q1 2019
5/7/2019
17.040.010.04426.0
Q4 2018
2/21/2019
16.61-0.01-0.04NA
Q3 2018
11/6/2018
15.80-0.19-0.76NA
Q2 2018
8/7/2018
17.62-0.16-0.64NA
Q1 2018
5/10/2018
19.97-0.19-0.76NA
Q4 2017
2/20/2018
18.480.853.405.4
Q3 2017
11/7/2017
16.840.020.08210.5
Q2 2017
8/8/2017
13.04-0.23-0.92NA
Q1 2017
5/9/2017
13.84-0.26-1.04NA
Q4 2016
2/28/2017
12.82-0.21-0.84NA
Q3 2016
11/7/2016
8.87-0.23-0.92NA
Q2 2016
8/9/2016
10.40-0.21-0.84NA
Q1 2016
5/9/2016
9.72-0.16-0.64NA
Q4 2015
2/29/2016
8.130.030.1267.8
Q3 2015
11/9/2015
17.88-0.19-0.76NA
Q2 2015
8/10/2015
21.110.020.08263.9
Q1 2015
5/11/2015
15.37-0.12-0.48NA
Q4 2014
3/2/2015
15.22-0.04-0.16NA
Q3 2014
11/10/2014
9.32-0.16-0.64NA
Q2 2014
8/11/2014
10.06-0.13-0.52NA
Q1 2014
5/12/2014
7.52-0.22-0.88NA
Q4 2013
2/27/2014
16.02-0.19-0.76NA
Q3 2013
11/8/2013
12.90-0.17-0.68NA
Q2 2013
8/7/2013
7.01-0.20-0.80NA
Q1 2013
5/8/2013
6.01-0.17-0.68NA
Q4 2012
2/25/2013
5.72-0.04-0.16NA
Q3 2012
11/8/2012
5.13-0.18-0.72NA
Q2 2012
8/6/2012
4.82-13.00-52.00NA
Q1 2012
5/7/2012
7.86-0.14-0.56NA
HALO PE History Chart
PeriodPriceAdj. EPSTTMPE
Q3 2022
11/8/2022
45.830.742.1621.2
Q2 2022
8/9/2022
43.330.531.9722.0
Q1 2022
5/10/2022
38.200.472.1018.2
Q4 2021
2/22/2022
32.790.422.0016.4
Q3 2021
11/2/2021
39.490.552.0819.0
Q2 2021
8/9/2021
40.440.661.7822.7
Q1 2021
5/10/2021
46.100.371.3135.2
Q4 2020
2/23/2021
47.210.500.9052.5
Q3 2020
11/2/2020
28.400.250.16177.5
Q2 2020
8/10/2020
28.640.19-0.26NA
Q1 2020
5/11/2020
24.82-0.04-0.55NA
Q4 2019
2/24/2020
21.43-0.24-0.50NA
Q3 2019
11/12/2019
16.77-0.17-0.27NA
Q2 2019
8/6/2019
17.15-0.10-0.29NA
Q1 2019
5/7/2019
17.040.01-0.35NA
Q4 2018
2/21/2019
16.61-0.01-0.55NA
Q3 2018
11/6/2018
15.80-0.190.3151.0
Q2 2018
8/7/2018
17.62-0.160.5233.9
Q1 2018
5/10/2018
19.97-0.190.4544.4
Q4 2017
2/20/2018
18.480.850.3848.6
Q3 2017
11/7/2017
16.840.02-0.68NA
Q2 2017
8/8/2017
13.04-0.23-0.93NA
Q1 2017
5/9/2017
13.84-0.26-0.91NA
Q4 2016
2/28/2017
12.82-0.21-0.81NA
Q3 2016
11/7/2016
8.87-0.23-0.57NA
Q2 2016
8/9/2016
10.40-0.21-0.53NA
Q1 2016
5/9/2016
9.72-0.16-0.30NA
Q4 2015
2/29/2016
8.130.03-0.26NA
Q3 2015
11/9/2015
17.88-0.19-0.33NA
Q2 2015
8/10/2015
21.110.02-0.30NA
Q1 2015
5/11/2015
15.37-0.12-0.45NA
Q4 2014
3/2/2015
15.22-0.04-0.55NA
Q3 2014
11/10/2014
9.32-0.16-0.70NA
Q2 2014
8/11/2014
10.06-0.13-0.71NA
Q1 2014
5/12/2014
7.52-0.22-0.78NA
Q4 2013
2/27/2014
16.02-0.19-0.73NA
Q3 2013
11/8/2013
12.90-0.17-0.58NA
Q2 2013
8/7/2013
7.01-0.20-0.59NA
Q1 2013
5/8/2013
6.01-0.17-13.39NA
Q4 2012
2/25/2013
5.72-0.04-13.36NA
Q3 2012
11/8/2012
5.13-0.18NANA
Q2 2012
8/6/2012
4.82-13.00NANA
Q1 2012
5/7/2012
7.86-0.14NANA
Quotes delayed 20 minutes

Email EnvelopeFree HALO Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Halozyme Therapeutics (HALO) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

HARP PE Ratio History
HBIO PE Ratio History
HCA PE Ratio History
HCWB PE Ratio History
HEPA PE Ratio History
HGEN PE Ratio History
HJLI PE Ratio History
HLTH PE Ratio History
HNGR PE Ratio History
HOLX PE Ratio History
How should the HALO historical PE ratio be determined?
Realizing that PE stands for Price to Earnings ratio, we need two values to compute it: stock price and earnings per share. The stock price at any given date is a known historical value, but what about the earnings number to use?

✔️Accepted answer: There are a number of different approaches when it comes to calculating a historical PE ratio for a company like Halozyme Therapeutics. We like to take our measurements on each of the past quarterly earnings reports. That only leaves the question of whether the earnings number at that quarterly report should be used on an annualized basis, or some other method. We approach this question using three different methods, on this HALO Historical PE Ratio page.

What is the average historical PE for HALO based on annualized quarterly earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use that quarter's earnings result annualized?

✔️Accepted answer: The HALO historical PE ratio using the annualized quarterly earnings method works out to 80.2.

What is the average historical PE for HALO based on trailing twelve month earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the trailing twelve months combined earnings result in the calculation?

✔️Accepted answer: The HALO historical PE ratio using the TTM earnings method works out to 43.3.

What is the average historical PE for HALO based on median TTM earnings?
As we look back through earnings history, what is the resulting PE calculation if at each measurement period we use the median earnings over the trailing twelve months and annualize that median result in the calculation?

✔️Accepted answer: The HALO historical PE ratio using the annualized median TTM earnings method works out to 2.

On this page we presented the HALO Historical PE Ratio information for Halozyme Therapeutics' stock. The average HALO historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 80.2. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average HALO historical PE based on this TTM earnings result method is 43.3. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this HALO historical PE result, against the recent PE: when this page was posted on 11/9/2022, the most recent closing price for HALO had been 49.71, and the most recent quarterly earnings result, annualized, was 2.96. Meanwhile, the most recent TTM earnings summed to 2.16. From these numbers, we calculate the recent HALO PE on 11/9/2022 based on annualized quarterly EPS was 16.8. Based on HALO's history, that recent PE is low relative to the historical average, with the recent PE 79.1% lower than the historical average PE across our data set for Halozyme Therapeutics. Looking at the recent HALO PE on 11/9/2022 based on TTM EPS, we calculate the ratio at 23.0. Based on HALO's history, that recent PE is low relative to the historical average, with the recent PE 46.9% lower than the average PE across our Halozyme Therapeutics data set with TTM EPS used in the calculation at each period.

Another interesting HALO historical PE Ratio calculation we look at is to take the median earnings per share of the last four quarters for HALO, and then annualize the resulting value... with that annualized number then being used in the PE calculation. To walk through this math for HALO, we start with the past four EPS numbers and we first sort them from lowest to highest: 0.42, 0.47, 0.53, and 0.74. We then toss out the highest and lowest result, and then take the average of those two middle numbers — 0.47 and 0.53 — which gives us the median of 0.50. Basically the way to think about this 0.50 number is this: for the trailing four earnings reports, 0.50 marks the "middle ground" number where HALO has reported a value higher than 0.50 half the time, and has reported a value lower than 0.50 half the time. Annualizing that median value then gets us to 2/share, which we use as the denominator in our next PE calculation. With 49.71 as the numerator (as of 11/9/2022), the calculation is then 49.71 / 2 = 24.9 as the HALO PE ratio as of 11/9/2022, based on that annualized median value we calculated.

For self directed investors doing their due diligence on HALO or any other given stock, valuation analysis for HALO can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Halozyme Therapeutics PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for HALO. Thanks for visiting, and the next time you need to research HALO Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.

Recommended: CGEN market cap history, Funds Holding SZK, Institutional Holders of WRLS.

 

HALO Historical PE Ratio | www.HistoricalPERatio.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.